What do healthcare SaaS founders need to understand about customer sales cycles?

Short Answer

Healthcare provider sales cycles are 9-18 months (vs. 3-6 months for general B2B). Budget approval is December-January. Clinical validation is required.

Full Explanation

A healthcare SaaS founder expects 3-month sales cycles like enterprise SaaS. Reality: healthcare providers have annual budget cycles (October approval, December lock), procurement processes (RFP requirements, vendor evaluation 6+ months), and clinical validation requirements (prove the product improves outcomes). Sales cycle timeline: Month 1-2 (initial discovery), Month 3-6 (clinical pilot proving efficacy), Month 7-10 (procurement and contract negotiation), Month 11-14 (budget approval and signature). Total: 12-18 months. This requires different cash management and fundraising strategy. Budget timing matters: healthcare budgets lock in December, so deals signed after December won't close until next December (even if contract is signed). This creates lumpy revenue. Founder honesty: "Our sales cycle is 12-18 months because healthcare providers require clinical evidence and annual budget approval. Our first three customers took 16, 14, and 12 months respectively. Once we have published clinical evidence (expected Q4 2026), sales cycles should compress to 10-12 months. We've modelled revenue with 18-month cash visibility and monthly working capital buffer." This shows maturity. Claiming 6-month sales cycles for healthcare signals naivety. Healthcare investors specifically evaluate: do you have published clinical evidence? Are you tracking sales pipeline against realistic timelines? This informs valuation and burn runway assessment.

Related Questions

How do you value a fintech company and what's unique about fintech intangibles?

Fintech valuations emphasise regulatory status, customer lock-in (payment networks), and data assets, with higher discou...

What are B2B SaaS customer concentration considerations?

High customer concentration (top customer >20% of revenue) is a major valuation discount for B2B SaaS — contract quality...

What are deep tech-specific valuation considerations?

Deep tech (AI, biotech, hardware, quantum) valuations depend heavily on proof-of-concept validation, IP strength, patent...

Want to see these concepts in action?

Discover how the Opagio Growth Platform puts intangible asset theory into practice.